Delivery Order SPE2DB22D2206-SPE2DB25FJC39
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) with a contract value of $6,400.76. This competitively awarded, firm fixed price delivery order was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. The contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $7,598.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units). This is a non-set-aside competitive award with performance completion scheduled for July 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location. This delivery order represents a child contract executed under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $6,467.94 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100 count) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitive award, structured as a firm fixed-price delivery order with no set-aside designation, is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,337.70 on July 21, 2025, for the supply of Vyvanse 20 mg capsules (100-count units). This firm fixed-price delivery order, which is expected to be completed by July 22, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Vyvanse is a prescription medication commonly used in...
- The Defense Logistics Agency awarded a $3,007.07 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. The contract was awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, under firm fixed pricing with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 20 mg capsules (100 count) with a ceiling value of $4,284.71. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025. The award was competitively procured with no set-aside designation, and performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this...
- The Defense Logistics Agency awarded a delivery order valued at $1,339.21 to AmerisourceBergen Drug Corp for Vyvanse 50 mg capsules (100-count packages) on July 21, 2025, with an ultimate completion date of July 22, 2025. The contract employs firm fixed pricing and is not set aside for any specific business category. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal healthcare vendor specializing in...
- The Defense Logistics Agency awarded a delivery order valued at $6,321.44 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Vyvanse is a prescription medication used in the treatment of attention deficit hyperactivity...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJC39Delivery Order
The Defense Logistics Agency awarded a $9,719.60 delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 50 mg capsules (100 count) on July 28, 2025, with a completion date of July 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being fulfilled from the company's location in Conshohocken, Pennsylvania. The delivery order represents a single-line procurement under AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. AmerisourceBergen Drug Corp serves as a major pharmaceutical distributor supporting federal medical procurement, particularly for military and veteran healthcare systems. This delivery order is issued under the company's prime IDC with the DLA valued at $999,999,999.00 and running through December 2026, which provides comprehensive pharmaceutical support to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Vyvanse (lisdexamfetamine dimesylate) is a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder and binge eating disorder within military and federal healthcare populations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.7k | 7/28/25 |